Mustang Bio Inc

NASDAQ:MBIOUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs in cell and gene therapies into potential cures for cancers and rare genetic diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR-T) therapies across multiple cancers, as well as lentiviral gene therapies for severe combined immunodeficiency. Its pipeline is focused in three core areas: CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors and gene therapies for rare genetic disorders. It is developing a CAR T therapy for hematologic malignancies in partnership with Fred Hutch targeting CD20 (MB-106). In partnership with St. Jude, its X-linked Severe Combined Immunodeficiency (XSCID) gene therapy programs (MB-117 and MB-217) are being developed under an exclusive license to develop a potentially curative treatment for XSCID, a rare genetic immune system condition.

Contact Information

Headquarters

377 PLANTATION STREETWORCESTER, MA, United States 01605

Phone

781-652-4500

Fax

302-531-3150

Executives

Executive Chairman of the Board

Michael Weiss

President, Chief Executive Officer, Director

Manuel Litchman

Interim Chief Financial Officer

James Murphy

Interim Chief Accounting Officer

Peter Carney

Director

Lindsay Rosenwald